CIMA LABS Commences Share Repurchasing Under Existing Buy-Back Authorization.Business Editors & Health/Medical Writers MINNEAPOLIS--(BUSINESS WIRE)--Nov. 5, 2001 CIMA LABS INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (Nasdaq:CIMA) today announced that it has commenced repurchasing its common stock on the open market under an existing plan whereby the Company can buy back up to $20 million of its shares. John M. Siebert, Ph.D., president and chief executive officer, said, "Reflecting CIMA's positive business outlook, we believe our stock represents an excellent value at current price levels. Our Board of Directors and senior management view this repurchasing activity as an expression of confidence in CIMA's future." About CIMA CIMA develops and manufactures prescription and over-the-counter products for pharmaceutical companies based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(TM). CIMA formulates a pharmaceutical company's active drug ingredient into a new, orally disintegrating dosage form A dosage form is the physical form of a dose of medication, such as a capsule or injection. The route of administration is dependent on the dosage form of a given drug. that dissolves quickly in the mouth without chewing chewing or mastication Up-and-down and side-to-side movements of the lower jaw, using the teeth to grind food for easier swallowing. During chewing, the tongue shapes food into a lump and saliva lubricates it for swallowing. or the need for water. Taste masking mask·ing n. 1. The concealment or the screening of one sensory process or sensation by another. 2. An opaque covering used to camouflage the metal parts of a prosthesis. agents may be used with the Company's fast-dissolve technologies to prevent or minimize the unpleasant taste associated with many active drug ingredients. CIMA currently manufactures five pharmaceutical brands utilizing its OraSolv and DuraSolv technologies: three prescription and two over-the-counter. The statements in this press release regarding the repurchase of CIMA common stock and CIMA's positive outlook, are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. A number of factors could cause actual results to differ materially from CIMA's assumptions and expectations. CIMA may repurchase up to $20 million of its common stock, or any lesser amount, depending on the trading price Trading price The price at which a security is currently selling. of its common stock, market conditions, or for other reasons. Additional factors that may cause actual results to differ from CIMA's assumptions and expectations include those set forth under the heading "Factors That Could Affect Future Results" included in CIMA's most recent SEC filings. All forward-looking statements are qualified by, and should be considered in conjunction with, such cautionary statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion